Skip to content

Addressing Unmet Needs with Partial Agonists at the D2 Receptor: MDD and SZ

2020 APA Scientific Conference

Please click "Next" if you did not attend this session
100%
The session met the stated learning objectives:
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
Present indications of D2 partial agonists in MDD and schizophrenia;
Explain how partial D2 agonists are being used in both MDD and schizophrenia;
Examine the short- and long-term existing data on the efficacy and safety of D2 receptor partial agonists in MDD and schizophrenia.
Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
The session was educationally relevant.
The presenter was educationally effective.
The session provided interactive opportunities.
The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice
Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
The session and presenter did NOT have commercial or other inappropriate bias.
Please provide any other comments you would like to share: